100% Pure Emu Oil (Simmia Holdings Pty Ltd)
Product Name
100% Pure Emu Oil
Sponsor
ARTG details
95322
Date of review outcome
Date of publication
Jun-2026
Outcome
Medicine is no longer permitted to be supplied
Is it safe to continue using this medicine?
No, continued use is not recommended as its safety is not considered acceptable for a listed medicine
What action should consumers take?
Seek advice from a health professional if you have been taking this medicine for rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ulcerative colitis, mucositis, inflammatory bowel disease, irritable bowel syndrome, stomach ulcers, balancing cholesterol levels, autoimmune skin conditions, psoriasis, eczema, rosacea, and bowel repair due to damage caused by chemotherapy.
Be aware immediate treatment of burns should be application of cold water for ten minutes and listed medicines should only be used for minor burns after initial first aid treatment. Medical advice should be sought for serious burns.
Consider whether this medicine is right for you based on it potentially not working as expected in relation to the treatment of aches, bites, dry skin and minor burns, and the relief of various forms and symptoms of arthritis, and the reduction of irritation and inflammation caused by skin disorders like eczema, dermatitis, psoriasis, nappy rash and cradle cap, and may not assist with hair regrowth, reduction of grey hairs, reduction of the visible signs of wrinkles, common skin and joint pains.
Be aware immediate treatment of burns should be application of cold water for ten minutes and listed medicines should only be used for minor burns after initial first aid treatment. Medical advice should be sought for serious burns.
Consider whether this medicine is right for you based on it potentially not working as expected in relation to the treatment of aches, bites, dry skin and minor burns, and the relief of various forms and symptoms of arthritis, and the reduction of irritation and inflammation caused by skin disorders like eczema, dermatitis, psoriasis, nappy rash and cradle cap, and may not assist with hair regrowth, reduction of grey hairs, reduction of the visible signs of wrinkles, common skin and joint pains.
Review scope
Targeted
Information reviewed
ARTG Record, Evidence, Labels, Manufacturing Documentation, Website
Issues related to safety
This medicine contains the ingredient Emu Oil, which requires the sponsor to hold a veterinary certificate indicating that the emus from which the raw material was extracted were healthy and fit for human consumption. The sponsor did not hold a veterinary certificate for this medicine.
The website for this medicine contained references to non-permitted claims as set out under 'What action should consumers take'. These claims are not permitted for listed medicines without prior evaluation or approval from the TGA. References to non-permitted claims have the potential to lead consumers to delay access to timely advice or treatment from a suitability qualified health professional when required, which may result in adverse outcomes.
The labels for this medicine were missing the mandatory warning statements for skin burns as set out under 'what actions should consumers take'. This warning statement is necessary to ensure the safe use of this medicine and to alert consumers to see a health professional if symptoms persist.
Whilst these issues are not acceptable for a listed medicine, the sponsor cancelled this medicine, and current data indicates this medicine is unlikely to pose an immediate risk to consumer health and safety.
The website for this medicine contained references to non-permitted claims as set out under 'What action should consumers take'. These claims are not permitted for listed medicines without prior evaluation or approval from the TGA. References to non-permitted claims have the potential to lead consumers to delay access to timely advice or treatment from a suitability qualified health professional when required, which may result in adverse outcomes.
The labels for this medicine were missing the mandatory warning statements for skin burns as set out under 'what actions should consumers take'. This warning statement is necessary to ensure the safe use of this medicine and to alert consumers to see a health professional if symptoms persist.
Whilst these issues are not acceptable for a listed medicine, the sponsor cancelled this medicine, and current data indicates this medicine is unlikely to pose an immediate risk to consumer health and safety.
Issues related to efficacy
The labels and website for this medicine contained claims specified in 'What action should consumers take?' above. However, these claims were not covered by the sponsor's certification that they held evidence to substantiate them.
Actions taken during the review
The TGA required the sponsor to correct the issues with this medicine. The sponsor cancelled this medicine and withdrew it from further supply.